Literature DB >> 9490680

Characterization of monoclonal antibodies that recognize canine CD34.

P A McSweeney1, K A Rouleau, P M Wallace, B Bruno, R G Andrews, L Krizanac-Bengez, B M Sandmaier, R Storb, E Wayner, R A Nash.   

Abstract

Using a polyclonal antiserum against canine CD34, we previously found that CD34 is expressed on canine bone marrow progenitor cells in a manner analogous to that found in humans. To further characterize CD34+ cells and to facilitate preclinical canine stem cell transplant studies, monoclonal antibodies (MoAbs) were raised to CD34. A panel of 10 MoAbs was generated that reacted with recombinant CD34 and with CD34+ cell lines and failed to react with CD34- cell lines. Binding properties of five purified MoAbs were determined by BIAcore analysis and flow cytometric staining, and several MoAbs showed high affinity for CD34. Two antibodies, 1H6 and 2E9, were further characterized, and in flow cytometry studies typically 1% to 3% of stained bone marrow cells were CD34+. Purified CD34+ bone marrow cells were 1.8- to 55-fold enriched for colony-forming unit-granulocyte-macrophage and for long-term culture initiating cells as compared with bone marrow mononuclear cells, whereas CD34- cells were depleted of progenitors. Three autologous transplants were performed with CD34+ cell fractions enriched by immunomagnetic separation. After marrow ablative total body irradiation (920 cGy), prompt hematopoietic recovery was seen with transplanted cell doses of </=1.1 x 10(7) /kg that were 29% to 70% CD34+. Engraftment kinetics were similar to those of dogs previously transplanted with approximately 10- to 100-fold more unmodified autologous marrow cells. This suggests that CD34+ is a marker not only of canine bone marrow progenitors but also for cells with radioprotective or marrow repopulating function in vivo. MoAbs to CD34 will be valuable for future studies of canine hematopoiesis and preclinical studies concerning stem cell transplantation, gene therapy, and ex vivo progenitor cell expansion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9490680

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

Authors:  Won Sik Lee; Yasuhiro Suzuki; Scott S Graves; Mineo Iwata; G M Venkataraman; Marco Mielcarek; Laura J Peterson; Susumu Ikehara; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-10       Impact factor: 5.742

2.  Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier.

Authors:  Monica S Thakar; Erlinda B Santos; Simon Fricker; Gary Bridger; Rainer Storb; Brenda M Sandmaier
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

3.  Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector.

Authors:  S E Suter; T A Gouthro; P A McSweeney; R A Nash; M E Haskins; P J Felsburg; P S Henthorn
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

4.  Evaluation of posttransplant methotrexate to facilitate engraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model.

Authors:  Monica S Thakar; Erlinda B Santos; Theodore A Gooley; George Sale; Rainer Storb; Hans-Peter Kiem; Brenda M Sandmaier
Journal:  Transplantation       Date:  2010-07-15       Impact factor: 4.939

5.  Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs.

Authors:  Michael H Goldschmidt; Jeffrey S Kennedy; Douglas R Kennedy; Hang Yuan; David E Holt; Margret L Casal; Anne M Traas; Elizabeth A Mauldin; Peter F Moore; Paula S Henthorn; Brian J Hartnett; Kenneth I Weinberg; Richard Schlegel; Peter J Felsburg
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs.

Authors:  Juan Fang; Eric S Jensen; Mary K Boudreaux; Lily M Du; Troy B Hawkins; Sevasti B Koukouritaki; Kenneth Cornetta; David A Wilcox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

7.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

Authors:  Lauri Burroughs; Marco Mielcarek; Marie-Térèse Little; Gary Bridger; Ron Macfarland; Simon Fricker; Jean Labrecque; Brenda M Sandmaier; Rainer Storb
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  Identification and characterization of canine dendritic cells generated in vivo.

Authors:  Marco Mielcarek; Kristin A Kucera; Richard Nash; Beverly Torok-Storb; Hilary J McKenna
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-07       Impact factor: 5.742

9.  Effect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation.

Authors:  Douglas R Kennedy; Kyle McLellan; Peter F Moore; Paula S Henthorn; Peter J Felsburg
Journal:  Biol Blood Marrow Transplant       Date:  2009-06       Impact factor: 5.742

10.  Evaluation of Tat-encoding bicistronic human immunodeficiency virus type 1 gene transfer vectors in primary canine bone marrow mononuclear cells.

Authors:  Narasimhachar Srinivasakumar; Michail Zaboikin; Tatiana Zaboikina; Friedrich Schuening
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.